Psoriatic Arthritis - Pipeline Review, H2 2020

November 2020 | 355 pages | ID: P8BDC2BEC63EN
Global Markets Direct

Abstracts

Psoriatic Arthritis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2020, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 9, 5, 13, 1, 25 and 9 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Psoriatic Arthritis- Overview
Psoriatic Arthritis- Therapeutics Development
Psoriatic Arthritis- Therapeutics Assessment
Psoriatic Arthritis- Companies Involved in Therapeutics Development
Psoriatic Arthritis- Drug Profiles
Psoriatic Arthritis- Dormant Projects
Psoriatic Arthritis- Discontinued Products
Psoriatic Arthritis- Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Psoriatic Arthritis, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Psoriatic Arthritis - Pipeline by 3SBio Inc, H2 2020
Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2020
Psoriatic Arthritis - Pipeline by Aclaris Therapeutics Inc, H2 2020
Psoriatic Arthritis - Pipeline by Affibody AB, H2 2020
Psoriatic Arthritis - Pipeline by Alpine Immune Sciences Inc, H2 2020
Psoriatic Arthritis - Pipeline by AltruBio Inc, H2 2020
Psoriatic Arthritis - Pipeline by Alvotech ehf, H2 2020
Psoriatic Arthritis - Pipeline by Amgen Inc, H2 2020
Psoriatic Arthritis - Pipeline by Avotres Inc, H2 2020
Psoriatic Arthritis - Pipeline by Bio-Thera Solutions Ltd, H2 2020
Psoriatic Arthritis - Pipeline by Biocad, H2 2020
Psoriatic Arthritis - Pipeline by Biocon Ltd, H2 2020
Psoriatic Arthritis - Pipeline by BioXpress Therapeutics SA, H2 2020
Psoriatic Arthritis - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Psoriatic Arthritis - Pipeline by Celltrion Inc, H2 2020
Psoriatic Arthritis - Pipeline by DM Bio Ltd, H2 2020
Psoriatic Arthritis - Pipeline by DNX Biopharmaceuticals Inc, H2 2020
Psoriatic Arthritis - Pipeline by Eli Lilly and Co, H2 2020
Psoriatic Arthritis - Pipeline by FYB202 GmbH & Co KG, H2 2020
Psoriatic Arthritis - Dormant Projects, H2 2020
Psoriatic Arthritis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Psoriatic Arthritis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020